Literature DB >> 26803534

Myxoma Virus Induces Ligand Independent Extrinsic Apoptosis in Human Myeloma Cells.

Mee Y Bartee1, Katherine M Dunlap1, Eric Bartee2.   

Abstract

INTRODUCTION: Multiple myeloma is a clonal malignancy of plasma B cells. Although recent advances have improved overall prognosis, virtually all myeloma patients still succumb to relapsing disease. Therefore, novel therapies to treat this disease remain urgently needed. We have recently shown that treatment of human multiple myeloma cells with an oncolytic virus known as myxoma results in rapid cell death even in the absence of viral replication; however, the specific mechanisms and pathways involved remain unknown.
MATERIALS AND METHODS: To determine how myxoma virus eliminates human multiple myeloma cells, we queried the apoptotic pathways that were activated after viral infection using immunoblot analysis and other cell biology approaches.
RESULTS: Our results indicate that myxoma virus infection initiates apoptosis in multiple myeloma cells through activation of the extrinsic initiator caspase-8. Caspase-8 activation subsequently results in cleavage of BH3 interacting-domain death agonist and loss of mitochondrial membrane potential causing secondary activation of caspase-9. Activation of caspase-8 appears to be independent of extrinsic death ligands and instead correlates with depletion of cellular inhibitors of apoptosis. We hypothesize that this depletion results from virally mediated host-protein shutoff because a myxoma construct that overexpresses the viral decapping enzymes displays improved oncolytic potential.
CONCLUSION: Taken together, these results suggest that myxoma virus eliminates human multiple myeloma cells through a pathway unique to oncolytic poxviruses, making it an excellent therapeutic option for the treatment of relapsed or refractory patients.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Caspase-8; Host protein shutoff; Oncolytics; Resistance; cIAPs

Mesh:

Year:  2015        PMID: 26803534      PMCID: PMC4811739          DOI: 10.1016/j.clml.2015.12.005

Source DB:  PubMed          Journal:  Clin Lymphoma Myeloma Leuk        ISSN: 2152-2669


  56 in total

Review 1.  The roles of Bid.

Authors:  M Degli Esposti
Journal:  Apoptosis       Date:  2002-10       Impact factor: 4.677

2.  Myxoma virus: propagation, purification, quantification, and storage.

Authors:  Sherin E Smallwood; Masmudur M Rahman; Dorothy W Smith; Grant McFadden
Journal:  Curr Protoc Microbiol       Date:  2010-05

Review 3.  Multiple myeloma.

Authors:  Antonio Palumbo; Kenneth Anderson
Journal:  N Engl J Med       Date:  2011-03-17       Impact factor: 91.245

Review 4.  Caspase-9.

Authors:  K Kuida
Journal:  Int J Biochem Cell Biol       Date:  2000-02       Impact factor: 5.085

5.  Systemic therapy of disseminated myeloma in passively immunized mice using measles virus-infected cell carriers.

Authors:  Chunsheng Liu; Stephen J Russell; Kah-Whye Peng
Journal:  Mol Ther       Date:  2010-03-16       Impact factor: 11.454

6.  The myeloma cell antigen syndecan-1 is lost by apoptotic myeloma cells.

Authors:  M Jourdan; M Ferlin; E Legouffe; M Horvathova; J Liautard; J F Rossi; J Wijdenes; J Brochier; B Klein
Journal:  Br J Haematol       Date:  1998-03       Impact factor: 6.998

7.  Infection and killing of multiple myeloma by adenoviruses.

Authors:  Julien S Senac; Konstantin Doronin; Stephen J Russell; Diane F Jelinek; Philip R Greipp; Michael A Barry
Journal:  Hum Gene Ther       Date:  2010-02       Impact factor: 5.695

8.  Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter.

Authors:  David Dingli; Kah-Whye Peng; Mary E Harvey; Philip R Greipp; Michael K O'Connor; Roberto Cattaneo; John C Morris; Stephen J Russell
Journal:  Blood       Date:  2003-11-06       Impact factor: 22.113

9.  Caspase-10 is the key initiator caspase involved in tributyltin-mediated apoptosis in human immune cells.

Authors:  Harald F Krug
Journal:  J Toxicol       Date:  2012-01-12

10.  Oncolytic virotherapy for hematological malignancies.

Authors:  Swarna Bais; Eric Bartee; Masmudur M Rahman; Grant McFadden; Christopher R Cogle
Journal:  Adv Virol       Date:  2011-10-29
View more
  16 in total

1.  Induction of tumor cell autosis by myxoma virus-infected CAR-T and TCR-T cells to overcome primary and acquired resistance.

Authors:  Ningbo Zheng; Jing Fang; Gang Xue; Ziyu Wang; Xiaoyin Li; Mengshi Zhou; Guangxu Jin; Masmudur M Rahman; Grant McFadden; Yong Lu
Journal:  Cancer Cell       Date:  2022-08-25       Impact factor: 38.585

2.  Poxviruses as Gene Therapy Vectors: Generating Poxviral Vectors Expressing Therapeutic Transgenes.

Authors:  Steven J Conrad; Jia Liu
Journal:  Methods Mol Biol       Date:  2019

3.  Systemic therapy with oncolytic myxoma virus cures established residual multiple myeloma in mice.

Authors:  Eric Bartee; Mee Y Bartee; Bjarne Bogen; Xue-Zhong Yu
Journal:  Mol Ther Oncolytics       Date:  2016-12-07       Impact factor: 7.200

4.  Myxoma Virus Optimizes Cisplatin for the Treatment of Ovarian Cancer In Vitro and in a Syngeneic Murine Dissemination Model.

Authors:  Bernice Nounamo; Jason Liem; Martin Cannon; Jia Liu
Journal:  Mol Ther Oncolytics       Date:  2017-08-09       Impact factor: 7.200

Review 5.  Potential of oncolytic viruses in the treatment of multiple myeloma.

Authors:  Eric Bartee
Journal:  Oncolytic Virother       Date:  2018-02-23

6.  The Oncolytic Virotherapy Era in Cancer Management: Prospects of Applying H-1 Parvovirus to Treat Blood and Solid Cancers.

Authors:  Assia L Angelova; Mathias Witzens-Harig; Angel S Galabov; Jean Rommelaere
Journal:  Front Oncol       Date:  2017-05-12       Impact factor: 6.244

7.  Ex Vivo Oncolytic Virotherapy with Myxoma Virus Arms Multiple Allogeneic Bone Marrow Transplant Leukocytes to Enhance Graft versus Tumor.

Authors:  Cameron L Lilly; Nancy Y Villa; Ana Lemos de Matos; Haider M Ali; Jess-Karan S Dhillon; Tom Hofland; Masmudur M Rahman; Winnie Chan; Bjarne Bogen; Christopher Cogle; Grant McFadden
Journal:  Mol Ther Oncolytics       Date:  2016-12-14       Impact factor: 7.200

Review 8.  Oncolytic virotherapy as an immunotherapeutic strategy for multiple myeloma.

Authors:  Daniel E Meyers; Satbir Thakur; Chandini M Thirukkumaran; Don G Morris
Journal:  Blood Cancer J       Date:  2017-12-05       Impact factor: 11.037

9.  Experimental African trypanosome infection suppresses the development of multiple myeloma in mice by inducing intrinsic apoptosis of malignant plasma cells.

Authors:  Nathan De Beule; Eline Menu; Mathieu J M Bertrand; Mérédis Favreau; Elke De Bruyne; Ken Maes; Kim De Veirman; Magdalena Radwanska; Afshin Samali; Stefan Magez; Karin Vanderkerken; Carl De Trez
Journal:  Oncotarget       Date:  2017-05-24

Review 10.  Oncolytic Viruses for Multiple Myeloma Therapy.

Authors:  Christine M Calton; Kevin R Kelly; Faiz Anwer; Jennifer S Carew; Steffan T Nawrocki
Journal:  Cancers (Basel)       Date:  2018-06-14       Impact factor: 6.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.